(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends that women at increased risk of breast cancer be prescribed tamoxifen or raloxifene for risk reduction, according to a final Recommendation Statement published online Sept. 24 in the Annals of Internal Medicine.
To update the 2002 USPSTF recommendations, researchers from the USPSTF reviewed evidence on the effectiveness, adverse effects, and subgroup variations of medication to reduce the risk of breast cancer. They specifically focused on the selective estrogen receptor modulators tamoxifen and raloxifene, and reviewed a meta-analysis of placebo-controlled trials to assess the benefits and harms of these medications.
Based on the findings, the researchers recommend that clinicians engage in shared, informed, decision making for women aged 35 years or older, at risk of breast cancer. For women with low risk for adverse medication effects who are at increased risk of breast cancer, clinicians should offer to prescribe risk-reducing medications (Grade B recommendation). For women who are not at increased risk of breast cancer, the USPSTF recommends against routine use of medications such as tamoxifen and raloxifene (Grade D recommendation).
"While these medications have some significant side effects, it is important that clinicians and women at high risk for breast cancer be aware of the options these drugs offer," USPSTF member Wanda Nicholson, M.D., M.P.H., M.B.A., said in a statement.
Explore further: Women at high breast cancer risk should consider preventive drugs: experts
More information: Full Text
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Women at high breast cancer risk should consider preventive drugs: experts
Jul 09, 2013
(HealthDay)—Women at high risk of breast cancer should discuss with their doctors the use of so-called chemopreventive drugs to reduce that risk, according to a new practice guideline issued by the American ...
USPSTF: evidence lacking for ankle brachial index screening
Sep 03, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) has found that there is currently insufficient evidence to weigh the benefits and harms of use of the ankle-brachial index (ABI) for screening ...
Drugs can cut breast cancer risk for some, task force finds
Apr 16, 2013
(HealthDay)—The drugs tamoxifen and raloxifene (Evista) could reduce the risk of breast cancer among women who are at high risk of developing the disease, a new report confirms.
Newly identified markers may predict who will respond to breast cancer prevention therapy
Jun 13, 2013
Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, ...
USPSTF: BRCA testing for women with family history
Apr 02, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends that BRCA1 and BRCA2 genetic testing be limited to women whose family histories are associated with an increased likelihood of having BRC ...
Recommended for you
Marriage associated with better cancer outcomes, study finds
13 hours ago
People who are married when diagnosed with cancer live longer than those who are not, report researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital. Married patients also tended to have cancers diagnosed ...
Researchers erase human brain tumor cells in mice
15 hours ago
Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of—and ultimately left no detectable trace of—brain tumor cells taken from adult ...
Long-term hormonal therapy in intermediate-risk PCa patients does not improve overall survival
17 hours ago
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there ...
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
19 hours ago
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate ...
Two-item questionnaire proves to be a valid depression screening tool for radiation therapy patients
19 hours ago
Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation ...
Protecting specific area of the brain during radiation therapy substantially reduces memory loss
19 hours ago
Protecting the stem cells that reside in and around the hippocampus – a C-shaped area in the temporal lobe on both sides of the brain associated with the ability to form and store memories – substantially reduces the ...
User comments
© Medical Xpress 2011-2013, Phys.org network
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends that women at increased risk of breast cancer be prescribed tamoxifen or raloxifene for risk reduction, according to a final Recommendation Statement published online Sept. 24 in the Annals of Internal Medicine.
To update the 2002 USPSTF recommendations, researchers from the USPSTF reviewed evidence on the effectiveness, adverse effects, and subgroup variations of medication to reduce the risk of breast cancer. They specifically focused on the selective estrogen receptor modulators tamoxifen and raloxifene, and reviewed a meta-analysis of placebo-controlled trials to assess the benefits and harms of these medications.
Based on the findings, the researchers recommend that clinicians engage in shared, informed, decision making for women aged 35 years or older, at risk of breast cancer. For women with low risk for adverse medication effects who are at increased risk of breast cancer, clinicians should offer to prescribe risk-reducing medications (Grade B recommendation). For women who are not at increased risk of breast cancer, the USPSTF recommends against routine use of medications such as tamoxifen and raloxifene (Grade D recommendation).
"While these medications have some significant side effects, it is important that clinicians and women at high risk for breast cancer be aware of the options these drugs offer," USPSTF member Wanda Nicholson, M.D., M.P.H., M.B.A., said in a statement.
Explore further: Women at high breast cancer risk should consider preventive drugs: experts
More information: Full Text
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Women at high breast cancer risk should consider preventive drugs: experts
Jul 09, 2013
(HealthDay)—Women at high risk of breast cancer should discuss with their doctors the use of so-called chemopreventive drugs to reduce that risk, according to a new practice guideline issued by the American ...
USPSTF: evidence lacking for ankle brachial index screening
Sep 03, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) has found that there is currently insufficient evidence to weigh the benefits and harms of use of the ankle-brachial index (ABI) for screening ...
Drugs can cut breast cancer risk for some, task force finds
Apr 16, 2013
(HealthDay)—The drugs tamoxifen and raloxifene (Evista) could reduce the risk of breast cancer among women who are at high risk of developing the disease, a new report confirms.
Newly identified markers may predict who will respond to breast cancer prevention therapy
Jun 13, 2013
Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, ...
USPSTF: BRCA testing for women with family history
Apr 02, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends that BRCA1 and BRCA2 genetic testing be limited to women whose family histories are associated with an increased likelihood of having BRC ...
Recommended for you
Marriage associated with better cancer outcomes, study finds
13 hours ago
People who are married when diagnosed with cancer live longer than those who are not, report researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital. Married patients also tended to have cancers diagnosed ...
Researchers erase human brain tumor cells in mice
15 hours ago
Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of—and ultimately left no detectable trace of—brain tumor cells taken from adult ...
Long-term hormonal therapy in intermediate-risk PCa patients does not improve overall survival
17 hours ago
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there ...
Fewer weeks of hormone therapy before radiation reduces side effects in intermediate risk PCa
19 hours ago
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate ...
Two-item questionnaire proves to be a valid depression screening tool for radiation therapy patients
19 hours ago
Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation ...
Protecting specific area of the brain during radiation therapy substantially reduces memory loss
19 hours ago
Protecting the stem cells that reside in and around the hippocampus – a C-shaped area in the temporal lobe on both sides of the brain associated with the ability to form and store memories – substantially reduces the ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment